Asterias Biotherapeutics Company Profile (NYSEMKT:AST)

Analyst Ratings

Consensus Ratings for Asterias Biotherapeutics (NYSEMKT:AST) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.63

Analysts' Ratings History for Asterias Biotherapeutics (NYSEMKT:AST)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2016Chardan CapitalInitiated CoverageBuy$5.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016Rodman & RenshawReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015MLV & Co.Reiterated RatingBuy$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2015Lake Street CapitalInitiated CoverageBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Asterias Biotherapeutics (NYSEMKT:AST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/16/2016Q116($0.14)($0.27)$1.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/29/2016Q415($0.13)($0.13)$1.07 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.11)($0.06)$1.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.11)($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.13)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2015($0.13)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Asterias Biotherapeutics (NYSEMKT:AST)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Asterias Biotherapeutics (NYSEMKT:AST)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Asterias Biotherapeutics (NYSEMKT:AST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/30/2016Stephen Lahue CarttCEOBuy10,000$2.40$24,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2016Richard T LebuhnDirectorBuy5,000$2.38$11,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2016Stephen Lahue CarttCEOBuy50,000$2.93$146,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2016Alfred D KingsleyDirectorBuy4,000$2.93$11,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016Natale S RicciardiDirectorBuy14,706$3.39$49,853.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Edward WirthinsiderSell2,880$6.00$17,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Katharine E. SpinkCOOSell3,760$6.00$22,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2015Andrew ArnoDirectorBuy5,000$4.32$21,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2015Pedro LichtingerCEOBuy128,205$3.90$499,999.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Scarsdale Equities LlcMajor ShareholderBuy60,000$5.93$355,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Asterias Biotherapeutics (NYSEMKT:AST)
DateHeadline
07/29/16 07:28 AMCurrent report No 16/2016 - [at noodls] - Statement on the application of Warsaw Stock Exchange corporate governance rules The Board of Directors of ASTARTA Holding N.V. with its corporate seat in Amsterdam, the Netherlands (the 'Company') presents ...
07/22/16 02:35 PMHow Many Asterias Biotherapeutics Inc (NYSEMKT:AST)'s Analysts Are Bullish? - Consumer Eagle
07/22/16 02:35 PMAsterias Biotherapeutics Inc's Stock Is Buy After Today's Huge Increase - Consumer Eagle
07/22/16 02:01 AMAusNet Services Ltd. :AST-AU: Earnings Analysis: For the six months ended March 31, 2016 : July 22, 2016 -
07/22/16 12:16 AMAusNet Services Ltd. :AST-AU: Earnings Analysis: 2016 By the Numbers : July 22, 2016 -
07/21/16 02:36 PMStock Moving Lower for the Month; Investor Update on Asterias Biotherapeutics, Inc. (:AST) - Engelwood Daily
07/20/16 10:42 AMAsterias Biotherapeutics Appoints Ryan Chavez as EVP of Finance and General Counsel - PR Newswire (press release)
07/19/16 08:00 PMAsterias Biotherapeutics : Appoints Ryan Chavez as EVP of Finance and General Counsel
07/19/16 02:36 PMAsterias Biotherapeutics Incorporated (NYSEMKT:AST) Short Interest Increased By 29.08% - Press Telegraph
07/19/16 08:48 AMInvestor Watch: Volatility Recap on Shares of: Asterias Biotherapeutics, Inc. (:AST) - Engelwood Daily
07/18/16 07:31 AMBRIEF-Asterias Biotherapeutics appoints Ryan Chavez as general counsel - Reuters
07/18/16 05:30 AMAsterias Biotherapeutics Appoints Ryan Chavez as EVP of Finance and General Counsel - [PR Newswire] - FREMONT, Calif., July 18, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative ...
07/17/16 07:20 AMNext Weeks Broker Price Targets For Asterias Biotherapeutics, Inc. (AST) - Fiscal Standard
07/16/16 02:35 PMIncreased Volatility Noted on Shares of: Asterias Biotherapeutics, Inc. (:AST) - Engelwood Daily
07/16/16 02:35 PMAsterias Biotherapeutics Incorporated (NYSEMKT:AST) Shorted Shares Increased By 0.48% - Consumer Eagle
07/15/16 10:28 AMCurrent report No 15/2016 - [at noodls] - Dates for filing periodical reports in 2016 The Board of Directors of ASTARTA Holding N.V. (the 'Company') informs about the following amendment to the current report No. 4/2016 of 28 January 2016. The ...
07/14/16 02:40 PMAre Analysts Bullish Asterias Biotherapeutics Inc (NYSEMKT:AST) After Last Week? - Press Telegraph
07/13/16 02:37 PMInvestor Update - Shares Lower in Session: Asterias Biotherapeutics, Inc. (:AST) - Telanagana Press
07/13/16 02:37 PMWhat's Propelling Asterias Biotherapeutics Inc to Decline So Much? - Consumer Eagle
07/12/16 05:49 AMStock Volatility Focus for: Asterias Biotherapeutics, Inc. (:AST) - Engelwood Daily
07/12/16 05:49 AMAsterias Biotherapeutics Completes Enrollment and Dosing for the First Efficacy Cohort of the AST-OPC1 SCiSTAR ... - PR Newswire (press release)
07/12/16 05:30 AMAsterias Biotherapeutics Completes Enrollment and Dosing for the First Efficacy Cohort of the AST-OPC1 SCiSTAR Phase 1/2a Clinical Trial in Complete Cervical Spinal Cord Injury - [PR Newswire] - The SCiSTAR study is being funded in part by a $14.3 million grant from the California Institute of Regenerative Medicine. "Successful completion of enrollment and dosing of these five patients in the first efficacy cohort receiving 10 million cells represents a critically important milestone in our AST-OPC1 clinical program for patients with complete cervical spinal cord injuries," said Steve Cartt, President and Chief Executive Officer.
07/10/16 07:20 AMAsterias Biotherapeutics Incorporated (NYSEMKT:AST) Shorted Shares Increased By 0.48% - Press Telegraph
07/07/16 02:35 PMNew Broker Ratings For Asterias Biotherapeutics, Inc. (AST) - FTSE News
07/07/16 02:35 PMAsterias Biotherapeutics, Inc. Stock Momentum Hits Weakness - CML News
07/06/16 01:07 PMETF’s with exposure to Asterias Biotherapeutics, Inc. : July 6, 2016 -
07/05/16 07:23 AMBroker Outlook For The Week Ahead Asterias Biotherapeutics, Inc. (AST) - Fiscal Standard
07/04/16 02:35 PMShare Performance Recap for: Asterias Biotherapeutics, Inc. (:AST) - Press Telegraph
06/29/16 02:35 PMInvestor News: Asterias Biotherapeutics Inc (NYSEMKT:AST) faces Investigation over possibleWrongdoing
06/23/16 10:39 AMCurrent report No 14/2016 - [at noodls] - The European Bank for Reconstruction and Development approved granting a new long-term loan for USD 20 million to ASTARTA to further finance its investment program. The proposed loan to ASTARTA Holding ...
06/21/16 06:00 AMAsterias Biotherapeutics Announces Oral Presentation and Participation in Panel Discussion at the ISSCR 14th Annual Meeting - [PR Newswire] - FREMONT, Calif., June 21, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative ...
06/20/16 01:02 PMETF’s with exposure to Asterias Biotherapeutics, Inc. : June 20, 2016 -
06/15/16 02:41 PMForm S-8 Asterias Biotherapeutics
06/15/16 02:41 PMInvestor Investigation over Potential Wrongdoing at Asterias Biotherapeutics Inc (NYSEMKT:AST)
06/14/16 04:07 PMASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/07/16 04:27 PMETF’s with exposure to Asterias Biotherapeutics, Inc. : June 7, 2016 -
06/07/16 10:50 AMASTERIAS BIOTHERAPEUTICS (AST) Andrews & Springer LLC Is Investigating Asterias Biotherapeutics, Inc. For Potential Breach of Fiduciary Duty
06/06/16 11:11 AMAsterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/06/16 07:38 AMIFC approved $25 million financing to ASTARTA - [at noodls] - The Board of Directors of International Financial Corporation (IFC) approved $25 million financing to ASTARTA in the form of working capital line. The Project will help the Company secure working capital ...
06/06/16 07:03 AMASTERIAS BIOTHERAPEUTICS (AST) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Asterias Biotherapeutics, Inc. For Potential Breach of Fiduciary Duty - [Business Wire] - Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Asterias Biotherapeutics, Inc.
06/05/16 10:29 AMInvestor trolling, media hype and fetal stem cells
06/03/16 02:40 PMStemCells to wind down operations after ending mid-stage study
06/03/16 01:55 AMCurrent report No 13/2016 - [at noodls] - Current report No 13/2016 The text version of this document is not available at the moment. The original content was posted at original link . Astarta Holding NV published this content on 03 June 2016 ...
06/01/16 11:02 AMChardan Capital Starts Asterias Biotherapeutics at Buy, $5.50 PT (NYSEMKT:AST) - Analysts estimated a revenue of $870.00K. Thrivent Financial For Lutherans bought a new position in shares of Asterias Biotherapeutics Inc (NYSEMKT:AST) during the fourth quarter, according to its most recent Form 13F filing with the SEC. Rodman & Renshaw ...
06/01/16 11:02 AMAre Analysts Bullish Asterias Biotherapeutics Inc (NYSEMKT:AST) After Last Week? - Rodman & Renshaw reissued a "buy" rating and set a $10.00 target price on shares of Asterias Biotherapeutics in a research note on Tuesday, May 17th. They now have a United States dollars 12 price target on the stock. The stock's market capitalization is $ ...
06/01/16 11:02 AMRecently Changed Price Targets On Asterias Biotherapeutics, Inc. (AST) - Chardan Capital's price target suggests a potential upside of 75.72% from the stock's current price. Out of 5 analysts covering Asterias Biotherapeutics (NYSEMKT:AST), 0 rate it a "Buy", 0 "Sell", while 0 "Hold". An institutional investor recently bought a ...
06/01/16 09:55 AMAsterias Biotherapeutics (AST): Moving Average Crossover Alert -
05/26/16 10:07 AMCurrent report No 12/2016 - [at noodls] - The Board of Directors of ASTARTA Holding N.V. with its corporate seat in Amsterdam, the Netherlands (the 'Company') informs that the following resolutions were adopted at the Annual General Meeting of ...
05/26/16 04:07 AMCurrent report No 11/2016 - [at noodls] - The Board of Directors of ASTARTA Holding N.V. with its corporate seat in Amsterdam, the Netherlands (the 'Company') informs that the following shareholders held at least 5% of voting rights at the Annual ...
05/23/16 12:49 PMChardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy Competitiveness - Chardan Capital Markets has started coverage of Asterias Biotherapeutics Inc (NYSE: AST) with a Buy rating and $5.50 price target, saying the company "has the potential to become a significant competitor in the emerging fields of cell therapy and regenerative medicine." "Asterias is developing novel stem-cell based therapies in neurology and oncology, with three clinical-stage product candidates targeting cervical spinal cord injury, acute myelogenous leukemia and non-small cell lung cancer," Chardan explained. "We believe that Asterias' key advantage in developing its cell therapies is its access to the extensive knowledge about the unique properties of human pluripotent cells through its relationships with Geron and BioTime," analyst Keay Nakae wrote in a note. Catalysts According to the analyst, the following events should act as catalyst for the stock over the next year: 1. "Interim efficacy data at six months from the second patient cohort in ...Full story available on Benzinga.com

Social

About Asterias Biotherapeutics

Asterias Biotherapeutics logoAsterias Biotherapeutics, Inc. is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer, and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia. The Company's product development is focused primarily on AST-OPC1 and AST-VAC2. The Company's lead therapeutic program focuses on the development of AST-OPC1 for spinal cord injury. AST-OPC1 product consists of glial progenitor cells, which are cells that become glial cells after injection. AST-VAC1 is an autologous product (using cells that come from the treated patient) consisting of mature antigen-presenting dendritic cells pulsed with ribonucleic acid (RNA) for the protein component of human telomerase (hTERT) and a portion of a lysosomal targeting signal (LAMP).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSEMKT
  • Symbol: AST
  • CUSIP:
Key Metrics:
  • Previous Close: $2.99
  • 50 Day Moving Average: $2.84
  • 200 Day Moving Average: $3.63
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $133.22M
  • Beta: 1.36
  • Current Year EPS Consensus Estimate: $-0.83 EPS
  • Next Year EPS Consensus Estimate: $-0.76 EPS
Additional Links: